The Blood-Brain Barrier: Implications For Chemotherapy And Its Delivery To The Brain In Primary And Metastatic Brain Tumor, A Novel Approach
Safila Naveed* Khadija Faheem, Faiza Bashir, Angela Maria Bhatti and Hafiza Sidra Salahuddin
Nearly 12.5 million new cancer cases are diagnosed worldwide each year.
Although new treatments have been developed, most new anticancer drugs that
are effective outside the brain have failed in clinical trials against brain tumors, in
part due to poor penetration across the BBB and the blood–brain tumor barrier.
Conventional treatment using radiation and intravenous chemotherapy often
prove unsuccessful primarily because the anticancer drugs fail to cross the BBB
in sufficient quantities. The focus is now on targeted drug therapy by not only
supplementing conventional chemotherapy and radiotherapy, but also by
preventing toxicity in normal tissues and drug resistance.Hence this work aims to
investigate the therapeutic regimen of primary and metastatic brain tumors and
drugs that fail to cross the BBB in sufficient quantities through conventional
treatment and a novel approach for the delivery of these drugs. A total number of
30 patients were enrolled from 5 different hospitals of Karachi. Each prescription
was scrutinized and the treatment line was noted down. The treatment strategy
was the main highlight of this study as to what was planned for the patient to get
the most effective result.
Share this article